May 25th
Adapt to Thrive logo
Career Development Course

ADAPT to Thrive

Would you like to hear how accomplished academics and research leaders failed and lived to tell the story? Get advice on how to build a research career when failing and taking risks is an integral part of it? Then register to attend the next ADAPT to Thrive event!

University College LondonUMC Utrecht and Institut Curie are partnering to host a virtual event on 25 May as part of the ADAPT to Thrive event series on failure and resilience.

By sharing the experiences of researcher at different career stages the ADAPT to Thrive event series provides early career researchers with support by showcasing how failure and success walk hand in hand.


Course in English



  • Normalise speaking out about failure and reducing stigma.
  • Help build a more resilient academic community by facilitating conversations and allowing early and mid-career researchers to find support networks.
  • Shift the perception of risk and encourage early career researchers to take new approaches to their careers and pursue unconventional ideas.

ECTS Information


Practical Informations

Practical Informations

WHERE: Zoom (the link will be sent to registered participants ahead of the event)

WHEN: Tuesday 25th May 2021, 16:00-18:00 (GMT)/ 17:00-19:00 (CET)

There is no registration fee for this course
Online Event
Online Event



  • Professor Emma Morris FMedSci, Professor of Clinical Cell and Gene Therapy, University College London. Emma Morris graduated from the University of Cambridge and subsequently trained at the Royal London Hospital, Guys Hospital and UCLH. She undertook a PhD in stem cell biology at the University of Cambridge prior to completing her postgraduate specialist training. She is now a UCL Professor and Director of the UCL Division of Infection and Immunity. She is also director of the UCLH Biomedical Research Centre Inflammation, Immunity and Immunotherapeutics research theme. She has made a significant contribution to the clinical translation of cell-based therapy for patients with immunodeficiencies. At UCLH she developed a critical infrastructure for clinical translation, including complex regulation and manufacturing. Her work led to the first clinical trial of T cell receptor-gene modified allogeneic cells for haematological malignancies. She leads the UK’s National Centre for Allogeneic haemopoietic stem cell transplantation in adults with primary immune deficiencies, and has been appointed National Clinical Lead for a new NHS England Commissioning Policy.
  • Professor Jeffrey M. Beekman, Professor of Cellular Disease Models, University of Utrecht. Jeffrey Beekman obtained a PhD in molecular immunology and performed multiple postdocs in molecular and cell biology within various immunological settings. In October 2010, he became principal investigator at the UMC Utrecht and started a novel translational research line focusing on developing novel therapeutic strategies for cystic fibrosis. His research is focused on exploring new ways to individualise clinical care and improve drug development by using laboratory-grown miniature organs from patient-derived airway and intestinal stem cells or organoids. His research has been awarded with the ‘Best Translational research prize 2012-2014’ from the Dutch Respiratory Society (NRS) and ‘Best translational article 2013 by the Dutch Pediatric Society, as well as the Gerd Doring award of the European CF Society (ECFS). In 2017, he received the ECFS award, becoming the ECFS person-of-the-year, the European Respiratory Society Excellence Award for Research in Cystic Fibrosis and the Willy van Heumen prize.
  • Professor Dominique Stoppa-Lyonnet, Head of the Department of Genetics at Institut Curie, Professor of Genetics, Paris Descartes University. Professor Dominique Stoppa-Lyonnet heads up the Department of Genetics at Institut Curie. She sits on the Oncogenetics Board of the French National Cancer Institute (INCa). She was a member of the Scientific and Medical Board of the French Biomedicine Agency (ABM) from 2005 to 2015 and the French National Consultative Ethics Committee (CCNE) from 2005 to 2013. She specializes in the diagnosis of predisposition to cancer, particularly breast and ovarian cancer. She works in clinical genetics and in the laboratory, where her research focuses on rare DNA repair disorders and the genetic epidemiology of predisposition to breast and ovarian cancer, as well as the treatment of women at high risk of these cancers. She played a key role in opposing the patents of the BRCA1 and BRCA2 genes awarded by the European Patent Office. She was co-rapporteur of two CCNE opinions on the ethical issues relating to pre-natal and pre-implantation genetic diagnosis, and non-invasive prenatal testing. Finally, she coordinated a report on the role of pre-natal and pre-implantation testing for hereditary forms of cancer, at the request of the ABM and INCa. In March 2014, she became a Paris city councillor for the fifth arrondissement, and has been a metropolitan councillor since January 2016.

Keynote speakers

This list of speakers may still change


 in collaboration with UMC Utrecht and Institut Curie


  • University College London